A Study to Evaluate the Safety of Dacomitinib for the First Line Treatment of Participants in India With Metastatic Non-Small-Cell Lung Cancer (NSCLC) With Change in a Gene
A Study to Evaluate the Safety of Dacomitinib for the First Line Treatment of Participants in India With Metastatic Non-Small-Cell Lung Cancer (NSCLC) With Change in a Gene. Single Arm Study to Evaluate the Safety of Dacomitinib for the First Line Treatment of Participants in India With Metastatic
Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Activating Mutations.
Category & Conditions: Cancer
Medicine: VIZIMPRO® TABLETS(DACOMITINIB)
ClinicalTrials.gov Identifier (NCT): NCT04511533
Protocol ID: A7471064
PrintDownloadOpen Plain Language Summary Result: Click here